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ABSTRACT
MicroRNAs (miRNAs) are a type of small non-coding
RNAs that are often play important roles in carcinogene-
sis, but the carcinogenic mechanism of miRNAs is still
unclear. This study will investigate the function and the
mechanism of miR-638 in carcinoma (GC). The expres-
sion of miR-638 in GC and the DNA copy number of miR-
638were detected by real-timePCR. The effect ofmiR-638
on cell proliferation was measured by counting kit-8
assay. Different assays, including bioinformatics algo-
rithms (TargetScanandmiRanda), luciferase report assay
and Western blotting, were used to identify the target
gene of miR-638 in GC. The expression of miR-638 target
gene in clinical CRC tissues was also validated by
immunohistochemical assay. From this research, we
found that miR-638 was downregulated in GC tissues
compared with corresponding noncancerous tissues
(NCTs), and theDNAcopynumberofmiR-638was lower in
GC than NCTs, which may induce the corresponding
downregulation of miR-638 in GC. Ectopic expression of
miR-638 inhibited GC cell growth in vitro. Subsequently,
we identiﬁed that PLD1 is the target gene of miR-638 in
GC, and silencing PLD1 expression phenocopied the
inhibitory effect of miR-638 on GC cell proliferation. Fur-
thermore, we observed that PLD1 was overexpressed in
GC tissues, and high expression of PLD1 in GC predicted
poor overall survival. In summary, we revealed that miR-
638 functions as a tumor suppressor in GC through
inhibiting PLD1.
KEYWORDS gastric cancer, miR-638, cell proliferation,
PLD1
INTRODUCTION
MicroRNAs (miRNAs) are endogenous 19–25 nt RNAs that
play important gene-regulatory roles in animals and plants
through binding to the 3′untranslated region (3′UTR) of target
mRNAs, and they can take part in cell development, differ-
entiation and proliferation (Bartel, 2009; Sreekumar et al.,
2011). Studies have shown that miRNAs played important
roles in the progression of various cancers over the past few
years, including gastric carcinoma (GC) (Esquela-Kerscher
and Slack, 2006; Cho, 2010). However, the biological func-
tions and molecular mechanisms of many miRNAs in GC
remain unclear.
GC is one of the most common human malignant cancers
worldwide, about one million new GC cases and 723,000
deaths are estimated to have occurred in 2012, accounting
for 8% of the total cases and 10% of total deaths (http://
globocan.iarc.fr). Over 70% of new cases and deaths occur
in developing countries (Jemal et al., 2011). Many miRNAs
were reported to be associated with GC development in
the past decade, including miR-146a (Yao et al., 2013),
miR-204-5p (Zhang et al., 2015), miR-486 (Oh et al., 2011),
miR-192 (Jin et al., 2011), miR-215 (Jin et al., 2011),
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miR-34b/c (Suzuki et al., 2010), miR-29a (Cui et al., 2011),
miR-409-3p (Li et al., 2012a), and miR-296-5p (Li et al.,
2014). These reports indicate that miRNAs play important
roles in CRC development and progression, providing new
avenues for GC diagnostic and therapeutic application (Ma
et al., 2012). Although many research teams have devel-
oped new GC therapies recently years, further deeply
investigations on molecular mechanisms underlying GC
carcinogenesis are urgently needed to improve GC diagno-
sis and therapy.
We previously identiﬁed some differentially expressed
miRNAs that could serve as prognostic and diagnostic
factors for colorectal cancer (CRC) and determined that
some of these deregulated miRNAs appeared to be highly
related to the tumor prognosis (Huang et al., 2010; Huang
et al., 2011; Song et al., 2014; Yin et al., 2014; Zhang et al.,
2014; Zhang et al., 2015). Among them, we found that miR-
638 is also down-regulated in GC as it in CRC. In the
current study, we comprehensively investigate the biologi-
cal functions and underlying molecular mechanism of miR-
638 in GC carcinogenesis. The enhanced expression of
miR-638 can inhibit cell proliferation in vitro. Furthermore,
phospholipase D1 (PLD1), a putative cell apoptosis sup-
pressor in GC, is characterized as a direct and functional
target of miR-638, which provides a possible regulation
pathway for PLD1 and a candidate target forthediagnostics
and treatment of GC.
RESULTS
Expression of miR-638 is down-regulated in GC tissues
As our previous research has found that miR-638 is down-
regulated in CRC (Huang et al., 2011; Zhang et al., 2014),
we intend to clarify whether miR-638 is down-regulated in
GC. To validate this issue, we examined the mature miR-638
expression level in 64 GC tissues using qRT-PCR. The
result showed that the miR-638 expression was down-reg-
ulated in 36 of 64 (56.25%) GC tissues when compared to
the corresponding NCTs (P < 0.001, Fig. 1A and 1B).
Because the deletion of DNA sequence coding for miRNAs
can result in the downregulation of corresponding miRNAs,
so we checked the pri-miR-638 copy number by qPCR in 24
pairs of GC tissues and NCTs to determine the reason of
miR-638 downregulation in GC. Interestingly, we found that
pri-miR-638 copy number was lower in GC tissues compared
with their NCT counterparts (P < 0.05, Fig. 1C), suggesting
that down-regulation of miR-638 in GC was modulated by
the loss of DNA copy number.
However, we did not observe signiﬁcant association
between miR-638 expression in GC tissues and overall
survival (OS) of GC patients (P > 0.05, Fig. 1D). In addition,
miR-638 expression was not signiﬁcantly associated
with gender, age, tumor location, size, stage, and grading
(P > 0.05).
MiR-638 represses GC cell proliferation in vitro
The down-regulation of miR-638 in GC suggests that it may
involve in GC tumorigenesis. Cell proliferation assay
revealed that miR-638 overexpression signiﬁcantly reduced
the growth rates of MKN-45 and SGC-7901 cells (P < 0.05,
Fig. 2A), and colony formation assay conﬁrmed that miR-638
inhibited the proliferation function of GC cells (P < 0.05,
Fig. 2C). In contrast, silencing miR-638 expression signiﬁ-
cantly promoted the growth of MKN-45 and SGC-7901 cells
(P < 0.05, Fig. 2B). In conclusion, all these data show that
miR-638 has the function of growth inhibitory.
MiR-638 directly binds to the 3′UTR of PLD1
To elucidate the mechanism underlying miR-638-mediated
suppression of cell proliferation, we used two computer-
aided algorithms, TargetScan and miRanda, to search for
potential target genes of miR-638. Among the 12 potential
tumor-related targets, 7 genes were signiﬁcantly down-reg-
ulated in MKN-45 and SGC-7901 cells transfected with miR-
638 and were considered to be the candidate targets of miR-
638 (Fig. 3A). Based on these data and our previous results
in CRC (Zhang et al., 2014), we focused on PLD1 and DEF6
for the subsequent analysis. The effects of the two candidate
targets on cell proliferation were performed on MKN-45 and
SGC-7901 cells using PLD1- or DEF6-speciﬁc siRNA. The
results indicated that silencing PLD1 expression signiﬁcantly
decreased cell proliferation in both of MKN-45 and SGC-
7901, which was not observed in the GC cells with silenced
DEF6 expression (Fig. 3B). Taken together, these results
suggest that PLD1 is a potential target gene of miR-638 in
GC.
To further verify that PLD1 is a direct target gene of miR-
638 in human GC, we generated a luciferase reporter plas-
mid which carried the mutated binding site of miR-638 in the
PLD1 3′UTR. (Fig. 3C), and found that miR-638 had no
effect on the activity of luciferase with mutant 3′UTR of PLD1
in HEK-293T, MKN-45, and SGC-7901 (Fig. 3D), suggesting
the sequence-speciﬁc inhibiting of miR-638 on the PLD1
expression. In line with these results, the endogenous PLD1
protein level was also decreased in miR-638-overexpression
GC cells and could be restored in miR-683-depleted GC
cells (Fig. 3E).
MiR-638 represses proliferation through directly
targeting PLD1 in human GC cells
To further examine whether PLD1 is a direct functional target
of miR-638 in GC cells, we performed a series of functional
restoration assays. As shown in Fig. 4A, the proliferation of
MKN-45 and SGC-7901 cells transfected with si-PLD1 were
signiﬁcantly decreased (Fig. 4A). Also, in miR-638 trans-
fection group, the proliferation ability of GC cells were
decreased, whereas anti-miR-638 could not restore cell
proliferation in PLD1-knockdown GC cells (Fig. 4B).
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Furthermore, we revealed that PLD1 over-expression could
signiﬁcantly promoted cell proliferation, which could not be
repressed by either the exogenous or endogenous overex-
pression of miR-638 (Fig. 4C–E). Taken together, all of these
results proved that miR-638 inhibits cell proliferation via
directly targeting PLD1.
PLD1 levels are negatively correlated with miR-638
expression and GC prognosis
To further evaluate the relationship between miR-638 and
PLD1 in human GC, PLD1 expression levels in GC tissues
and paired NCTs were examined by IHC assay. As Fig. 5A
and 5B showed, PLD1 protein expression in GC was
upregulated in 71/120 cases compared with paired NCTs,
and was inversely correlated with the miR-638 levels (P <
0.05, Fig. 5C), which suggested that the increased PLD1
expression in GC was caused by miR-638 under-expression.
Survival analyses revealed that increased PLD1 protein
levels (score 2 or 3) were associated with shorter survival
time (P = 0.0272, Fig. 5D). After adjusting from tumor size,
grading, and stage, multivariate analyses showed that PLD1
expression was an independent risk factor for survival
(Table S1). Patients with higher PLD1 expression presented
a higher risk of death (HR = 3.3049, 95% CI = 1.213–6.375,
P < 0.05) (Tables S1 and S2). Taken together, these data
suggest that PLD1 appears to be a new prognostic factor for
GC.
DISCUSSION
Nowadays, more than 2,000 miRNAs have been identiﬁed in
human, as an important gene regulated factor, it has been
identiﬁed as a key regulation factor for the tumor cell prolif-
eration, migration, and invasion. Down-regulation of miR-638
was ﬁrst identiﬁed in human non-small-cell lung cancer
(NSCLC) tissues (Li et al., 2012b). Our previous work
showed that miR-638 was downregulated in human CRC,
and loss of miR-638 promotes CRC cell proliferation (Zhang
et al., 2014). Other groups found that the loss of miR-638
could promote cell invasion and a mesenchymal-like transi-
tion in CRC cells (Ma et al., 2014), and downregulation of
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Figure 1. The expression of miR-638 was down-regulated in GC. (A) The expression of miR-638 was tested by qRT-PCR in 64
paired GC and adjacent noncancerous tissues (NCTs). (B) The levels of miR-638 were obviously down-regulated in 56.25% tumor
tissues. (C) The DNA copy number of miR-638 was checked by qPCR in 24 paired GC and NCTs. (D) Kaplan-Meier analysis of the
effect of the miR-638 expression on overall survival of 64 GC patients.
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(Xia et al., 2014). These data suggest a key role of miR-638
in human tumorigenesis.
GC is the second leading cause of global cancer mortality
and most of GC patients are diagnosed with advanced-stage
diseases (Cidon et al., 2013). As miR-638 had been veriﬁed
to be down-regulated in CRC, we want to clarify whether it is
also abnormal in human GC. We checked the expression of
miR-638 in 64 paired of GC tissues and NCTs, and observed
signiﬁcantly down-regulation of miR-638 in GC, which was in
consistent with a previous report (Shrestha et al., 2014).
The miR-638 gene is an intronic miRNA located on the
ﬁrst intron of DNM2. Our previous study revealed promoter
methylation is a potential mechanism accounting for the
down-regulation of the miR-638 in CRC. Copy number
variants (CNV) are the other notable structural variations in
the human genome that inﬂuence gene expression. Several
studies have examined the CNVs of miRNAs and revealed
their potential consequences (Ding et al., 2010; Wang et al.,
2014). We observed that the copy numbers of pri-miR-638
were decreased in GC compared with NCT samples, sug-
gesting that it account for, at least partly, the downregulation
of miR-638 in GC. However, for the relative small case
number in this study, these ﬁndings should be conﬁrmed in
an enlarged GC cohort in the future study.
In this study, we found that loss of miR-638 repressed cell
proliferation and colony formation in GC via its direct target,
PLD1. In addition to affecting proliferation, the role of miR-
638 in metastasis is another important aspect that must be
considered in future researches. PLD1 is an enzyme that
can convert phospholipid to phosphatidic acid (PA), and two
isoforms of phosphatidylcholine-speciﬁc PLD, PLD1 and
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Figure 2. MiR-638 inhibits GC cell proliferation in vitro. (A and B) Ectopic expression of miR-638 repressed the proliferation of
MKN-45 and SGC-7901 cells, whereas silencing miR-638 expression enhanced the cellular growth rate of MKN-45 and SGC-7901
cells. (*P < 0.05). (C) The colony formation assay was also applied to conﬁrm the ability of miR-638 on colony formation.
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and/or activity levels in various cancers (Zhang and Froh-
man, 2014). Our present study showed that PLD1 is over-
expressed in GC tissues compared with adjacent NCTs, and
PLD1 appears to be a new prognostic factor for GC.
Although upregulation of PLD1 plays an important role in
increasing cell proliferation, the molecular mechanisms
mediating PLD1 expression in GC cells are still unclear. The
expression of PLD1 was reported to be induced in GC cells
by infecting with cagA-positive H. pylori (Kang et al., 2013).
We reported here that loss of miR-638 caused overexpres-
sion of PLD1 in GC cells. This mechanism explicated the
reason of PLD1 overexpression in GC cells in a post-tran-
scriptional regulation level. The present study showed that
miR-638 is frequently down-regulated in GC, which partly
attributed to the copy number of miR-638 locus; and miR-
638 functions as a new repressor of GC cell proliferation. In
addition, PLD1 identiﬁed as functional target of miR-638 in
this study, was upregulated in GC and was closely related to
the prognosis of GC patients. These results suggest that
miR-638/PLD1 signalling could be a useful marker in GC and
potential therapeutic targets for the treatment of GC patients.
MATERIALS AND METHODS
Cell lines and clinical samples
HEK-293T cell line was purchased from the American Type Culture
Collection (ATCC), and human GC cell lines (MKN-45 and SGC-
WT UTR  5′
5′









































































































































































































Figure 3. Identiﬁcation of PLD1 as the target of miR-638. (A) Validation of the microarray results in both MKN-45 and SGC-7901
cells using qRT-PCR. A panel of 12 genes were indeed down-regulated by miR-638. (B) Proliferation assays performed on MKN-45
and SGC-7901 cells transfected with si-PLD1 or si-DEF6. Depleted PLD1 expression showed the most obvious growth repression
effect. (C) Schematic of the wild-type (WT) or mutant-type (MT) 3′UTRs of the PLD1 plasmids. The complementary site of the seed
region of miR-638 was selected for mutation. The free energy of hybrids between miR-638 and PLD1 was −21.1 kcal/mol.
(D) Relative luciferase activity assays of luciferase reporter plasmids containing PLD1WTor MT 3′UTR were performed in cells (HEK-
293T, MKN-45, and SGC-7901). Luciferase activity was determined 48 h after transfection and normalized to the Renilla luciferase
activity. (E) The protein levels of PLD1 were determined by Western blotting in MKN-45 and SGC-7901 cells transfected with miR-638
mimic, miR-638 inhibitor or the corresponding NC. Beta-actin served as an internal control.
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7901) were purchased from Shanghai Meixuan. All of the media
(Hyclone, USA) were supplemented with 10% fetal bovine serum
(FBS) (Gibco, USA). SGC-7901, MKN45, and HEK-293T cells were
cultured in DMEM.
A total of 64 pairs of human primary GC tissues and their adja-
cent NCTs were collected between 2008 and 2012 at the Afﬁliated
Hospital of Jiangnan University. The tissue samples were immedi-
ately snap-frozen in liquid nitrogen and were histologically con-
ﬁrmed. All of the human materials were obtained with informed
consent, and this project was approved by the Clinical Research
Ethics Committee of Afﬁliated Hospital of Jiangnan University.
DNA and RNA isolation
Genomic DNA was isolated using the General AllgGen Kit (Cwbio,
China) according to the manufacturer’s protocol. Total RNA was
extracted using RNAiso reagent (Takara, Japan). The concentrations
of DNA and RNA were determined using NanoDrop 2000 (Thermo,
USA).
Complementary DNA (cDNA) was synthesized using the Prime-
Script RT reagent kit (TaKaRa, Japan). QRT-PCR analyses were con-
ducted to quantitate the relative mRNA expression using SYBR Premix
Ex Taq (TaKaRa), with β-actin as an internal control. Stem-loop qRT-
PCR assays using TaqMan miRNA probes (Applied Biosystems, USA)
were performed to quantify the levels of the mature miRNAs. The
reactions were incubated in 96- or 384-well optical plates at 95°C for
10 min, followed by 40 cycles of 95°C for 15 s and 60°C for 1 min. After
the reactions, the cycle threshold (Ct) data were determined using
default threshold settings, and the mean Ct was determined from the
duplicate PCRs. A comparativeΔCtmethodwas used to compare each
condition with the controls, and the values are expressed as 2−△Ct. The
relative levels of miRNAs were normalized to the levels of U6, a ubiq-
uitously expressed small nuclear RNA. The relative DNA copy numbers
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Figure 4. MiR-638 repressed GC cell proliferation by inhibiting PLD1. (A) PLD1 knockdown repressed MKN-45 and SGC-7901
cells growth, whereas upregulation of miR-638 in PLD1-depleted cells did not repress cell proliferation further. (B) MiR-638 silencing
promoted cell growth, but did not promote cell proliferation in PLD1-depleted GC cells. (C) The upregulation of PLD1 ORF markedly
promoted cell growth and abrogated miR-638-induced cell growth inhibition in MKN-45 and SGC-7901 cells. (D) MiR-638
overexpression promoted apoptosis, PLD1 overexpression repressed cell apoptosis and decreased the percentage of apoptotic cells
after miR-638 overexpression. (E) The protein level of PLD1 was measured by Western blotting. Signiﬁcant differences are indicated
with * (*P < 0.05; **P < 0.01).
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The miR-638 lentivirus expression vector pWPXL-miR-638 was con-
structed as described (Zhang et al., 2014). The 3′UTRs of potential
miR-638 target genes were ampliﬁed from genomic DNA using Pri-
merSTAR Premix (TaKaRa). The ampliﬁed 3′UTRs were then cloned
into the region directly downstream of a CMV promoter-driven ﬁreﬂy
luciferase cassette in a pcDNA3.0 vector (p-Luc). The mutant 3′-UTR
of PLD1, which carried the mutated sequence in the complementary
site for the seed region of miR-638, was constructed based on the
p-Luc-PLD1 3′UTR-WT plasmid by overlap-extension PCR. The open
reading frame (ORF) of PLD1 was ampliﬁed and cloned into pWPXL.
Duplex siRNAs were purchased from GenePharma (Shanghai,
China). The anti-miRNA inhibitors (GenePharma, China) are single-
stranded nucleic acids chemically modiﬁed to speciﬁcally bind to and
inhibit endogenous miRNA molecules.
Lentivirus production and transduction
Virus packaging was performed in HEK 293T cells after co-transfec-
tion of pWPXL-638 or pWPXL-PLD1 with the packaging plasmid
psPAX2 and envelope plasmid pMD2.G using Lipofectamine 2000
(Invitrogen). Viruses were harvested 48 h after transfection, and viral
titers were determined. Target cells (1 × 105), including MKN-45 and
SGC-7901 cells, were infected with 1 × 106 recombinant lentivirus-
transducing units in the presence of 6 μg/mL polybrene (Sigma, MO).
Cell proliferation assay and colony formation assay
As the cell proliferation was quantiﬁed using the Cell Counting Kit-8
(CCK8; Dojindo Laboratories, Japan) according to the manufacturer’s
instructions. For the colony formation assays, 1000 cells of MKN-45
and 1500 cells of SGC-7901 cells were plated into each well of 6-well
plates and incubated in medium containing 10% FBS for 2 weeks.
The colonies were ﬁxed with methanol and stained with 0.1% crystal
violet in 20% methanol for 20 min. The number of colonies containing
more than about 30 cells was counted using an inverted microscope.
Luciferase assay
Approximately 5,000 HEK-293T cells or 10,000 GC cells (MKN-45
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Figure 5. Upregulation of PLD1 is inversely correlated with the miR-638 expression in GC. (A) Immunohistochemical staining of
PLD1 in 120 tumor tissues and adjacent noncancerous tissues (NCTs). Brown cytoplasmic PLD1 staining was observed in GC cells
but was nearly absent in normal mucosal epithelia. (B) PLD1 protein expression was frequently increased in the tumor tissues
(59.3%) compared with the matched NCTs. (C) The expression levels of PLD1 were negatively correlated with the miR-638
expression levels in the GC tissues (P = 0.0062). (D) Overall survival analysis based on the expression levels of PLD1. The groups
were ranked according to the PLD1 staining intensity. The patients with high PLD1 expression (scored 2 or 3) showed poor prognosis
compared with low PLD1 expression (scored 0 or 1) patients (P = 0.0272).
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cotransfected with 50 nmol/L of miR-638 mimic (or NC), 50 ng of the
luciferase reporter, and 10 ng of the pRL-CMV Renilla luciferase
reporter using 0.5 μL Lipofectamine 2000 (Invitrogen, USA) per well.
After 48-h of transfection, the luciferase activities were quantiﬁed
using a dual-luciferase reporter assay (Promega, USA).
Western blot
Harvested proteins were ﬁrst separated by 10% sodium dodecyl
sulphate-polyacrylamide gel electrophoresis and then transferred to
nitrocellulose membranes (Millipore, USA). The membranes were
blocked with 5% nonfat milk and incubated with a mouse anti-PLD1
polyclonal antibody at a dilution of 1:500 (Cell signal, USA) or a
mouse anti-beta-actin monoclonal antibody at a dilution of 1:500
(Sigma, USA). The membranes were subsequently incubated with a
goat anti-mouse horseradish peroxidase secondary antibody
(Sigma, USA). The protein complex was detected using enhanced
chemiluminescence reagents (Pierce, France). Endogenous beta-
actin was used as the internal control.
Immunohistochemistry (IHC)
Tissue arrays were constructed using 120 paired GC tissues and NCTs.
Immunohistochemical staining was performed on 4 μm sections of
parafﬁn-embedded tissues to determine the expression level of PLD1
protein. In brief, the slides were incubated in PLD1 antibody (Cell signal,
USA) diluted 1:400 at 4°C overnight. The subsequent steps were per-
formed using the EnVision™ FLEX High pH visualisation system
according to the manufacturer’s instructions (DAKO, Demark). The
PLD1proteinscorewasestimatedbasedon theoverall stainingstrength.
Statistical analysis
The results were presented as the mean ± standard error of the mean
(SEM). The data were subjected to two-tailed Student t test (P < 0.05)
unless otherwise speciﬁed (χ2 test or Spearman’s correlation). Cox
proportional hazards regression analysis was used to estimate the
hazard ratios (HRs) and the 95% conﬁdence intervals (CIs). A value
of P < 0.05 was considered to be statistically signiﬁcant. The SPSS
16.0 package (IBM, USA) was used for the statistical analyses.
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